Dr. Moffitt’s research focuses on bacterial pathogenesis and host interactions with common human pathogens such as Streptococcus pneumoniae and Staphylococcus aureus. Her work has identified several novel pneumococcal proteins that confer protection against colonization of the nasopharynx and may be candidate components of a pneumococcal protein subunit vaccine. To study these proteins, she is investigating their interaction with the host immune system, specifically the role of activation of the innate immune system in acquisition of protective adaptive immune responses. Dr. Moffitt’s work also investigates bacterial RNA expression profiles in human infection. The overall goal of her research is to identify factors employed by bacteria to facilitate disease and to understand the mechanisms of immunity to infection. The long-term goal of her work is to use these findings to guide the development of preventive and treatment strategies for common bacterial infections.


Dr. Moffitt received her undergraduate degree at Wellesley College and her medical degree from University of Vermont College of Medicine. She completed her internship and residency training in pediatrics at Hasbro Children’s Hospital of Brown Medical School followed by fellowship in pediatric infectious diseases at Boston Children’s Hospital. She joined the faculty of the Division of Infectious Diseases at Boston Children’s Hospital in 2010.


Publications powered by Harvard Catalyst Profiles

  1. Analysis of Staphylococcus aureus transcriptome in pediatric soft tissue abscesses and comparison to murine infections. Infect Immun. 2021 Feb 01. View abstract
  2. Process intensification for production of Streptococcus pneumoniae whole-cell vaccine. Biotechnol Bioeng. 2020 06; 117(6):1661-1672. View abstract
  3. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. Clin Infect Dis. 2019 01 18; 68(3):365-372. View abstract
  4. Evaluation of the Role of stat3 in Antibody and TH17-Mediated Responses to Pneumococcal Immunization and Infection by Use of a Mouse Model of Autosomal Dominant Hyper-IgE Syndrome. Infect Immun. 2018 05; 86(5). View abstract
  5. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine. 2017 03 01; 35(9):1306-1315. View abstract
  6. Acute lymphoblastic leukemia in a patient with MonoMAC syndrome/GATA2 haploinsufficiency. Pediatr Blood Cancer. 2016 10; 63(10):1844-7. View abstract
  7. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016; 12(2):383-92. View abstract
  8. T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins. Clin Vaccine Immunol. 2015 Aug; 22(8):909-16. View abstract
  9. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. 2014 May; 82(5):2079-86. View abstract
  10. Allograft-Transmitted Histoplasma capsulatum Infection in a Solid Organ Transplant Recipient. J Pediatric Infect Dis Soc. 2013 Sep; 2(3):270-3. View abstract
  11. Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine. PLoS One. 2012; 7(8):e43445. View abstract
  12. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine. 2012 Jun 19; 30(29):4316-22. View abstract
  13. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood. 2012 Mar 22; 119(12):2819-28. View abstract
  14. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011 Jun; 23(3):407-13. View abstract
  15. Cell Host and Microbe. TH17-based vaccine design for prevention of Streptococcus pneumoniae colonization. 2011; 9(2):158-65. View abstract